NeuBase Therapeutics Valuation

Is NBSE * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NBSE * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NBSE *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NBSE *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NBSE *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for NBSE *. This is calculated by dividing NBSE *'s market cap by their current preferred multiple.
What is NBSE *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$6.32m

NBSE * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does NBSE *'s PB Ratio compare to its peers?

The above table shows the PB ratio for NBSE * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2x
XCUR Exicure	3.9x	n/a	US$6.3m
KTTA Pasithea Therapeutics	0.4x	n/a	US$6.4m
RESP Respiratorius	2.6x	n/a	SEK 69.9m
ROQ Roquefort Therapeutics	0.9x	n/a	UK£4.6m
NBSE * NeuBase Therapeutics	0.4x	-25.8%	Mex$6.3m

Price-To-Book vs Peers: NBSE * is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (1.7x).

Price to Earnings Ratio vs Industry

How does NBSE *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: NBSE * is good value based on its Price-To-Book Ratio (0.4x) compared to the Global Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is NBSE *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NBSE * PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NBSE *'s Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.